Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 696 internationalen Medien
Ad-hoc-Meldung: Gleich zu Wochenbeginn prozentual dreistellig? Der frühe Vogel…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LCUL | ISIN: US14888U1016 | Ticker-Symbol: CN2
Tradegate
28.03.25
16:10 Uhr
22,430 Euro
-0,340
-1,49 %
Branche
Pharma
Aktienmarkt
S&P SmallCap 600
1-Jahres-Chart
CATALYST PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
CATALYST PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
22,45022,59030.03.
22,26023,28028.03.

Aktuelle News zur CATALYST PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
CATALYST PHARMACEUTICALS Aktie jetzt für 0€ handeln
DoCatalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win3
DoJim Cramer on Catalyst Pharmaceuticals (CPRX): 'That's My Kind of Stock!'2
24.03.CPRX stock soars to all-time high of $24.8 amid robust growth10
01.03.Catalyst Pharmaceuticals (NASDAQ:CPRX) Given Buy Rating at HC Wainwright7
28.02.Stephens raises Catalyst Pharma price target to $40, maintains overweight4
27.02.Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today6
27.02.Catalyst Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)3
27.02.CPRX Q4 Earnings Beat, Firdapse Sales Boost Revenues, Stock Up2
27.02.Catalyst Pharmaceuticals up 5% on 2025 revenue guidance5
26.02.Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update132Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net...
► Artikel lesen
26.02.CATALYST PHARMACEUTICALS, INC. - 8-K, Current Report-
26.02.CATALYST PHARMACEUTICALS, INC. - 10-K, Annual Report2
12.02.Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 20256
04.02.Beyond The Numbers: 6 Analysts Discuss Catalyst Pharmaceuticals Stock5
04.02.Baird starts Catalyst Pharma with Outperform, $28 target6
29.01.Nilsine Partners LLC Invests $700,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)16
23.01.Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies8
21.01.CATALYST PHARMACEUTICALS, INC. - 8-K, Current Report-
21.01.Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE in Japan145CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing...
► Artikel lesen
10.01.Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Expected to Rise, HC Wainwright Analyst Says9
Seite:  Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1